Pfizer Inc. reported fourth‑quarter 2025 results that beat consensus estimates, with adjusted earnings of $0.66 per share versus a $0.57 consensus and revenue of $17.56 billion, topping the $16.9‑$17.1 billion range of analyst expectations. GAAP earnings were a $0.29‑per‑share loss, but the adjusted figure reflected a 15.8% beat driven by strong performance in the non‑COVID portfolio and disciplined cost‑realignment savings.
Compared with the prior year, Q4 2025 revenue fell 3% to $17.56 billion, but the non‑COVID segment grew 9% operationally, offsetting a decline in COVID‑19 vaccine sales. In Q4 2024 Pfizer generated $17.8 billion in revenue and an adjusted EPS of $0.63; full‑year 2024 revenue was $63.6 billion with an adjusted EPS of $3.11. The year‑over‑year shift shows the company’s pivot from pandemic‑driven sales to a broader therapeutic mix.
Segment‑level data highlight the drivers of the earnings beat: Abrysvo, oncology biosimilars, Eliquis, the Prevnar family, and the Vyndaqel family all contributed to revenue growth, while the decline in COVID‑19 product sales was largely absorbed by the cost‑realignment program. The program, which is on track to deliver $4.5 billion in savings by year‑end 2025 and an additional $1.2 billion by 2027, is a key lever for restoring pre‑pandemic operating margins.
Pfizer reaffirmed its 2026 full‑year guidance, projecting revenue of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. The guidance range is slightly below analyst expectations for EPS, a factor that contributed to a muted market reaction. Management expressed confidence that the company’s pipeline—particularly in oncology and obesity—will sustain growth as the COVID‑19 business continues to contract.
"With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth," said Chairman and CEO Albert Bourla. "Looking ahead, 2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts," he added. CFO David Denton noted that the cost‑saving mission supports the goal of returning to pre‑pandemic operating margins and driving operating efficiencies.
Pre‑market trading showed a modest decline in investor sentiment, with the stock down about 1.2%. Analysts cited the guidance’s modest upside relative to expectations, the ongoing decline in COVID‑19 product sales, and upcoming patent cliffs as headwinds that tempered enthusiasm despite the earnings beat.
The results underscore Pfizer’s strategic shift from a pandemic‑centric model to a diversified portfolio focused on oncology, obesity, and other high‑growth areas. The company’s ability to generate earnings growth while managing costs positions it well for long‑term value creation, even as it navigates the transition away from COVID‑19 revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.